Hypertrophic Cardiomyopathy (HCM) Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

The "Hypertrophic Cardiomyopathy (HCM) - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Hypertrophic Cardiomyopathy (HCM)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hypertrophic Cardiomyopathy (HCM) Epidemiology

The Hypertrophic Cardiomyopathy (HCM) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypertrophic Cardiomyopathy (HCM) epidemiology segmented as the Prevalent Cases of Hypertrophic Cardiomyopathy (HCM), Diagnosed Cases of Hypertrophic Cardiomyopathy (HCM), Type-specific Cases of HCM, Gender-specific Cases of HCM. The report includes the Prevalent scenario of Hypertrophic Cardiomyopathy (HCM) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Hypertrophic Cardiomyopathy (HCM) Epidemiology

The epidemiology segment also provides the Hypertrophic Cardiomyopathy (HCM) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Hypertrophic Cardiomyopathy (HCM) Associated in 7MM countries was estimated to be 1,064,053 cases in 2020 and expected to increase at a CAGR of 0.47% for the study period, i.e., 2018-2030.

• As per the estimates, United States has the highest prevalent population of Hypertrophic Cardiomyopathy (HCM) in 7MM.
• Among the EU5 countries, Germany had the highest prevalent population of Hypertrophic Cardiomyopathy (HCM). On the other hand, Spain had the lowest number of cases in 2020.

Report Highlights

• 10-year Forecast of Hypertrophic Cardiomyopathy (HCM) epidemiology
• 7MM Coverage
• Prevalent Cases of Hypertrophic Cardiomyopathy (HCM)
• Diagnosed Cases of Hypertrophic Cardiomyopathy (HCM)
• Type-specific Cases of HCM
• Gender-specific Cases of HCM

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Hypertrophic Cardiomyopathy Epidem Overview at a Glance

3.1. Patient Share (%) Distribution of Hypertrophic Cardiomyopathy in 2018

3.2. Patient Share (%) Distribution of Hypertrophic Cardiomyopathy in 2030

4. Executive Summary of Hypertrophic Cardiomyopathy

5. Disease Background and Overview

5.1. Introduction

5.2. Risk Factors

5.3. Symptoms

5.4. Types of HCM

5.5. Molecular Genetics basis

5.6. Pathophysiology

5.6.1. Cardiac abnormalities

5.6.2. Genetic abnormalities

5.7. Disease Stages and Progression

5.7.1. Stages of HCM

5.7.2. Clinical progression of HCM

5.8. Manifestations

5.9. Clinical workup

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Patient Population of HCM

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Hypertrophic Cardiomyopathy in the United States

6.4.2. Diagnosed cases of Hypertrophic Cardiomyopathy in the United States

6.4.3. Gender-specific Prevalence of Hypertrophic Cardiomyopathy in the United States

6.4.4. Type-specific Prevalence of Hypertrophic Cardiomyopathy in the United States

6.5. EU5

6.5.1. Germany

6.5.2. France

6.5.3. Italy

6.5.4. Spain

6.5.5. United Kingdom

6.6. Japan

7. Treatment and Management

7.1. Pharmacological management

7.2. Non-pharmacologic therapy

7.3. Treatment Guidelines

7.3.1. American Heart Association/American College of Cardiology (AHA/ACC) guideline

7.3.2. European Society of Cardiology (ESC) Guidelines

8. Patient Journey

9. Case Reports

10. Organizations contributing toward Hypertrophic Cardiomyopathy

11. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/770p9g

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005335/en/